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Abstract
 
Natural killer (NK) cells express multiple activating receptors that initiate signaling cascades
through DAP10- or immunoreceptor tyrosine-based activation motif–containing adapters, includ-
ing DAP12 and FcR
 
 
 
. Among downstream signaling mediators, the guanine nucleotide exchange
factor Vav1 carries out a key role in activation. However, whether Vav1 regulates only some or
all NK cell–activating pathways is matter of debate. It is also possible that two other Vav family
molecules, Vav2 and Vav3, are involved in NK cell activation. Here, we examine the relative
contribution of each of these exchange factors to NK cell–mediated cytotoxicity using mice
lacking one, two, or all three Vav proteins. We found that Vav1 deficiency is sufficient to disrupt
DAP10-mediated cytotoxicity, whereas lack of Vav2 and Vav3 profoundly impairs FcR
 
 
 
- and
DAP12-mediated cytotoxicity. Our results provide evidence that these three Vav proteins function
specifically in distinct pathways that trigger NK cell cytotoxicity.
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Introduction
 
NK cells express multiple activating receptors with diverse
structures and specificities. In mice, prototypic receptors
include NKG2D, Ly49D, Ly49H, and the low affinity re-
ceptor for IgG, Fc
 
 
 
RIIIa. NKG2D recognizes endogenous
MHC class I–related molecules including, the retinoic acid–
inducible proteins Rae1
 
 
 
-
 
 
 
, the minor histocompatibility
antigen H60, and the UL16-binding proteinlike transcript
(MULT; references 1, 2). These molecules are expressed at
high levels primarily in virally infected and tumor cells (1, 2).
Ly49D triggers killing of allogeneic bone marrow cells and
Chinese hamster ovary (CHO) cells by recognizing murine
and hamster class I molecules (3, 4). Ly49H mediates se-
lective recognition of m157, a murine cytomegalovirus–
encoded class I–like molecule that is expressed on infected
cells (5, 6). Fc
 
 
 
RIIIa promotes lysis of IgG-coated target cells
by antibody-dependent, cell-mediated cytotoxicity (ADCC).
NKG2D, Ly49D, Ly49H, and Fc
 
 
 
RIIIa lack cytoplasmic
signaling elements and can deliver stimulatory signals only
by associating with transmembrane adaptor proteins. Ly49D
and Ly49H signal through DAP12 (also called KARAP),
whereas Fc
 
 
 
RIIIa associates with the 
 
 
 
 chain of Fc recep-
tors (FcR
 
 
 
) and CD3
 
 
 
 (7, 8). DAP12, FcR
 
 
 
, and CD3
 
 
 
contain immunoreceptor tyrosine-based activation motifs
(ITAMs) that are phosphorylated and function as docking
sites for Syk and ZAP70 protein tyrosine kinases (7, 8).
NKG2D includes two isoforms that differ in their cytoplas-
mic domains and associated adaptors (9, 10). NKG2D-long
(NKG2D-L) signals through DAP10, a unique adaptor con-
taining a YxNM motif that recruits phosphatidylinositol-
3-kinase (PI-3K; reference 11) and Grb-2. NKG2D-short
(NKG2D-S) associates with both DAP10 and DAP12 (9, 10).
Syk, ZAP70, and PI-3K initiate signaling cascades that lead
to activation of mitogen-activated protein kinases (MEKs),
phospholipase C (PLC)
 
 
 
, Ca
 
2
 
 
 
 mobilization, secretion of
IFN-
 
 
 
, and release of cytotoxic granules that contain per-
forin and granzymes (7, 8).
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Vav proteins are critical signaling mediators that connect
protein tyrosine and inositol kinases with effector responses
in NK cells (12, 13). Vav proteins include three closely
related guanine nucleotide exchange factors (Vav1, Vav2,
and Vav3) that activate small GTP-binding proteins be-
longing to the Rho-Rac/Cdc42 family, including Rac1,
RhoA, and RhoG (14). Rac1 sequentially activates p21-
activated kinase 1 (PAK1), MEK, and extracellular signal-
regulated kinase (ERK)1/2. In addition, Vav proteins perform
adaptor functions by binding the Src homology 2 domain-
containing leukocyte phosphoprotein (SLP)76, which is
part of a complex including PLC
 
 
 
 and the linker for acti-
vation of T cells (LAT; references 14, 15). In vitro studies
demonstrated that Vav1, Vav2, and Rac1 are activated in
human NK cells after challenge with tumor cells (16, 17)
or engagement of Fc
 
 
 
RIIIa (17), integrins (18, 19), and
NKG2D (20) with cognate ligands or specific antibodies.
Moreover, blocking Vav1 or Rac1 function using antisense
oligonucleotides for Vav1 or a dominant-negative form of
Rac1 inhibits NK cell adhesion to target cells, cytotoxicity
and secretion of IFN-
 
 
 
 (16, 17, 20). Consistent with these
results, in vivo studies demonstrated that Vav1 deficiency
reduces “natural” cytotoxicity, the ability of NK cells to
lyse various tumor cells (21, 22). However, the impact of
Vav1 deficiency on ADCC was controversial (21, 22) and
INF-
 
 
 
 secretion was not affected in Vav1
 
ko
 
 mice (21), sug-
gesting that Vav1 may not regulate all NK cell effector
functions. The possible involvement of other Vav family
members in NK cell activation has not been addressed in
vivo.
Here, we investigate the requirement for Vav proteins in
cytotoxicity mediated by several different activating NK
cell receptors using mice lacking one, two, or three Vav
proteins. We show that lack of Vav1 primarily impairs the
NKG2D–DAP10 cytolytic pathway, whereas lack of Vav2
and Vav3 reduces cytotoxicity triggered by receptors that
signal through ITAM-containing adapters. Our findings
demonstrate an unexpected specialization of Vav proteins
in regulating different cytotoxic pathways.
 
Materials and Methods
 
Mice. 
 
Vav1
 
ko
 
, Vav2
 
ko
 
, Vav3
 
ko
 
, Vav2,3
 
ko
 
, Vav1,2,3
 
ko
 
, DAP10
 
ko
 
,
and DAP12
 
ko
 
 mice have been described previously (10, 23).
 
RNase Protection Assay (RPA). 
 
Riboprobes included cDNA
fragments of murine Vav1 (nucleotide [nt] 664–862), Vav2 (nt
652–800), and Vav3 (nt 676–852). RPA was performed by stan-
dard techniques.
 
Cytotoxicity Assays. 
 
NK cells were purified from spleens with
DX5 microbeads (Miltenyi Biotec), cultured for different periods
of time in RPMI 1640 with 10% heat-inactivated FCS (Hyclone)
and 1,000 U/ml rIL-2 (Roche) and tested against target cells by
standard 
 
51
 
Cr release assay. Target cells used to assess natural cyto-
toxicity included YAC-1, CHO, RMAS, RMAS-Rae1
 
 
 
 (10),
Baf3, and Baf3-m157 (6). ADCC was evaluated using EL-4 cells
coated with the anti-Thy1.2 antibody TIB-107 (American Type
Culture Collection). Cytotoxicity was blocked with antibodies
against Ly49D (4), Ly49H (6), or NKG2D (10). In some experi-
ments, NK cells were pretreated for 20 min at 37
 
 
 
C with the
MEK inhibitor PD98059 (Calbiochem) before the addition of
antibodies and 
 
51
 
Cr-labeled cells.
 
Biochemical Analysis. 
 
WT, DAP10
 
ko
 
, DAP12
 
ko
 
, Vav1
 
ko
 
, and
Vav1,2,3
 
ko
 
 NK cells were cultured for different periods of time in
IL-2. After incubation with mAb HB-197 (Fc block; American
Type Culture Collection) for 15 min on ice to block Fc recep-
tors, NK cells (4 
 
 
 
 10
 
6
 
/sample) were treated with biotinylated
anti–mouse NKG2D (1 
 
 
 
g/10
 
6
 
 cells) for 15 min on ice followed
by streptavidin (1.51 
 
 
 
g/10
 
6
 
 cells) at 37
 
 
 
C for 2 and 5 min. Al-
ternatively, NK cells were conjugated at 37
 
 
 
C for 5 min with
CHO cells. NK cell lysates were analyzed by SDS-PAGE and
immunoblotting using antibodies against pERK1/2 (Thr202/
Tyr204) and ERK1/2 (New England Biolabs Inc.).
 
Online Supplemental Material.
 
In Fig. S1, Vav1, 2, and 3 are
expressed in NK cells, but are not required for NK cell matura-
tion. Fig. S2 shows NKG2D-mediated cytotoxicity in Vav1
 
ko
 
and DAP10
 
ko
 
 NK cells. Fig. S3 depicts lysis of RMA-S/Rae1
 
 
 
and YAC-1 cells by Vav1,2,3
 
ko
 
 and Vav2,3
 
ko
 
 NK cells ex vivo
and early after IL-2 activation. In Fig. S4, Vav deficiency does
not affect conjugate formation between WT, Vav-deficient NK
cells, and target cells. Online supplemental material is available at
http://www.jem.org/cgi/content/full/jem.20031847/DC1.
 
Results and Discussion
 
Vav1, Vav2, and Vav3 Are Expressed in NK Cells, but Are
Not Required for NK Cell Maturation and Cell Surface Expres-
sion of Activating and Inhibitory Receptors.
 
To determine which
 
vav
 
 genes are expressed in NK cells, we performed a quanti-
tative RPA with riboprobes specific for individual Vav tran-
scripts. All three 
 
vav
 
 genes were expressed in primary mouse
NK cells. Vav1 and Vav3 transcripts were the most abun-
dant, whereas the 
 
vav2
 
 gene was expressed at low levels
(Fig. S1 A, available at http://www.jem.org/cgi/content/
full/jem.20031847/DC1). Consistent with the results of RPA
analyses, Vav1 and Vav3 proteins were expressed at very
high levels in IL-2–cultured NK cells, whereas the Vav2
protein was less abundant (Fig. S1 B). NK cell development
is normal in mice lacking Vav1 (21). Despite severe defects
in the production of mature T and B lymphocytes in the
periphery (23), healthy Vav1,2,3
 
ko
 
 mice (4–5 wk old) har-
bored normal NK cell numbers in the spleen, as did Vav1
 
ko
 
mice (Fig. S1 C). In addition, Vav1,2,3
 
ko
 
 and WT NK cells
expressed comparable levels of DX5, IL-2/15R
 
 
 
 (CD122),
NK1.1, NKG2D, Mac-1 (CD11b), and NKG2A on the
cell surface and similar percentages of the NK populations
expressed Ly49A, Ly49D, and Ly49H (Fig. S1 D and not
depicted). Thus, none of the Vav proteins appear to be es-
sential for NK cell maturation or surface expression of acti-
vating or inhibitory NK cell receptors.
 
Vav1 Protein Is Not Necessary for FcR
 
 
 
- and DAP12-medi-
ated Cytotoxicity.
 
To determine the function of Vav1 pro-
tein in ITAM-dependent signaling, we examined ADCC as
well as Ly49H/DAP12- and Ly49D/DAP12-mediated cyto-
toxicity in Vav1
 
ko
 
 and WT mice. Vav1
 
ko
 
 and WT NK cells
killed EL-4 cells coated with an anti-Thy1.2 antibody
equally well (Fig. 1 A). Similarly, Vav1
 
ko
 
 NK cells killed Baf3
cells expressing m157 (Baf3-m157; references 5, 6), but not
Baf3 cells transfected with a control plasmid (Fig. 1 B). Fi- 
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nally, Vav1-deficient NK cells efficiently lysed CHO cells in
a Ly49D-mediated manner (Fig. 1 C). We conclude that
FcRIIIA/FcR
 
 
 
-, Ly49H/DAP12-, and Ly49D/DAP12-
mediated cytotoxicity are largely Vav1 independent. Because
the DAP12 and FcR
 
 
 
 adapters recruit signaling mediators
through cytoplasmic ITAMs, our results indicate that ITAM-
mediated cytotoxicity in NK cells does not require Vav1.
 
Vav1 Protein Is Essential for DAP10-mediated Cytotoxicity.
 
NK cells express two isoforms of NKG2D: NKG2D-L and
NKG2D-S (9). NKG2D-L signals through DAP10, whereas
NKG2D-S signals through both DAP12 and DAP10. The
relative proportion of NKG2D-L and NKG2D-S in NK cells
varies during IL-2 activation. NK cells isolated ex vivo pre-
dominantly express NKG2D-L (9), although some NKG2D-S
is also present (unpublished data). Early after IL-2 activa-
tion (6–10 d), NK cells up-regulate NKG2D-S. After pro-
longed culture with IL-2 (10–30 d), NKG2D-S expression
decreases and NKG2D-L again becomes predominant (9,
10). To determine the function of Vav1 in NKG2D/
DAP12- and NKG2D/DAP10-mediated cytotoxicity, we
compared cytotoxicity of Vav1
 
ko
 
 and WT NK cells at
different time points during culture with IL-2. Target cells
included RMAS transfectants expressing Rae1
 
 
 
 (RMAS-
Rae1
 
 
 
), control RMAS transfectants, and YAC-1 cells, which
express NKG2D ligands and, hence, are lysed to some extent
in an NKG2D-dependent fashion (1). All experiments were
performed with or without a mAb against NKG2D to pre-
cisely define the proportion of target cell lysis mediated by
NKG2D. When evaluated for NKG2D-mediated lysis of
RMAS-Rae1
 
 
 
, Vav1
 
ko
 
 (day 0) were significantly less effi-
cient than WT NK cells (Fig. 2 A). This difference was less
pronounced when Vav1
 
ko
 
 were tested during culture with
IL-2 (days 6–12), but again became substantial after extended
culture (days 12–30; Fig. 2 A). NKG2D-mediated lysis of
YAC-1 was also affected by the lack of Vav1 (Fig. 2 B). The
severity of this deficit varied in a temporal pattern similar to
that observed for lysis of RMAS-Rae1
 
 
 
, but was less pro-
nounced, especially at day 0. We speculate that the few
NKG2D–DAP12 receptor complexes present in fresh NK
cells may be sufficient to trigger YAC-1 killing or may syn-
ergize with a yet unknown receptor mediating NKG2D-
independent lysis of YAC-1. In summary, the IL-2/time-
dependent deficit of RMAS-Rae1
 
 
 
 and YAC-1 lysis caused
by Vav1 deficiency precisely mirrored the prevalence of
NKG2D-L/DAP10 signaling and paralleled that previously
observed in DAP10-deficient NK cells (Fig. S2, available at
http://www.jem.org/cgi/content/full/jem.20031847/DC1,
and reference 10). Therefore, we conclude that the NKG2D–
DAP10 pathway is largely Vav1 dependent.
 
Vav2 and Vav3 Proteins Are Required for FcR
 
 
 
- and
DAP12-mediated Signaling.
 
Vav2 is expressed in human
NK cells and plays a central role in NK cell–mediated cyto-
toxicity (24). In addition, NK cells express Vav3 (Fig. S1, A
and B). Thus, Vav1 may not be required for ITAM signaling
due to either preferential use of Vav2 and/or Vav3 in this
pathway or simple redundancy of the Vav proteins. To test
these hypotheses, we analyzed the impact of individual and
combined Vav1, Vav2, and Vav3 deficiencies on NK cell–
mediated cytotoxicity. Lack of Vav2 or Vav3 alone did not
significantly affect FcR
 
 
 
-, DAP12-, or DAP10-mediated
killing at any time point (unpublished data). In contrast, lack
of all Vav proteins completely abrogated ADCC (Fig. 3 A)
and severely reduced lysis of Baf3-m157 (Fig. 3 B). How-
ever, Vav1,2,3
 
ko
 
 NK cells were able to partially lyse Baf3-
m157 in a Ly49H-mediated manner at high E:T ratios (15–
20%). In addition, Ly49D-mediated lysis of CHO cells by
Vav1,2,3
 
ko
 
 NK cells remained surprisingly intact (Fig. 3 C).
Lack of all three Vav proteins caused a marked reduction in
NKG2D-mediated lysis of RMAS-Rae1
 
 
 
 and YAC-1 (Fig.
S3, A and B, available at http://www.jem.org/cgi/content/
full/jem.20031847/DC1). This defect was more profound
than that observed in Vav1
 
ko
 
 mice and was evident in resting
as well as in IL-2–activated NK cells at any time during cul-
ture. We conclude that lack of all three Vav isoforms results
in a more substantial defect in NK cell–mediated cytotoxic-
Figure 1. ITAM-dependent cytotoxicity in Vav1ko mice. Cytotoxicity
of Vav1ko NK cells was tested against the following: (A) EL-4 cells with or
without an anti-Thy1.2 mAb, (B) Baf-3-m157 and mock-transfected Baf-3
with or without a blocking mAb against Ly49H, and (C) CHO cells with
or without a blocking anti-Ly49D mAb. NK cells were cultured in IL-2
for 10–15 d, contained  98% NK1.1 /CD3  cells. Vav1ko and WT NK
cells exhibited comparable percentages of Ly49H  and Ly49D  cells. 
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ity than does Vav1 deficiency alone and affects both DAP10-
mediated and ITAM-dependent cytotoxicity. The unex-
pected ability of Vav1,2,3
 
ko
 
 NK cells to lyse CHO cells in a
Ly49D-mediated manner may suggest that Ly49D/DAP12
signaling is Vav independent. Alternatively, NK cell recep-
tors for CHO cells may include one or more as yet unidenti-
fied Vav-independent receptors in addition to Ly49D. These
receptors may synergize with Ly49D or provide costimula-
tion to Ly49D, allowing Ly49D signals to reach the thresh-
old required for cytotoxicity.
To determine whether Vav2 and Vav3 proteins are pref-
erentially used for ITAM signaling or Vav proteins are re-
dundant, we tested FcR
 
 
 
- and DAP12-mediated killing in
Vav2/3 double deficient mice. Vav2,3
 
ko
 
 NK cells completely
lacked the capacity to carry out ADCC (Fig. 3 D) and had an
obvious defect in Ly49H-mediated killing (Fig. 3 E). Lysis of
RMAS-Rae1
 
 
 
 (Fig. S3 C) and YAC-1 cells (Fig. S3 D) by
Vav2,3
 
ko
 
 NK cells isolated ex vivo or cultured with IL-2
(short or long periods of time) was variably reduced, probably
due to conserved NKG2D/DAP10-mediated signaling and
dependent on the relative expression of NKG2D-L/NKG2D-S
isoforms in the different NK cell populations tested. We
conclude that Vav2/Vav3 and Vav1 are not redundant and
that Vav2 and Vav3 proteins specialize in ITAM signaling.
 
Vav Deficiency Disrupts ERK1/2 Activation Triggered by the
DAP10 and DAP12 Pathways.
 
ERK1/2 activation is crit-
ical for promoting NK cell–mediated cytotoxicity (12). Be-
cause lack of Vav proteins impairs DAP10- and DAP12-
Figure 2. NKG2D-dependent cytotoxicity in Vav1ko mice. Cytolitic activity of Vav1ko NK cells against RMA-S, RMA-S/Rae1  (A), and YAC-1
(B) in the presence of a blocking anti-NKG2D mAb or control mAb. Effector cells included freshly isolated NK cells (day 0) and NK cells cultured in IL-2 for 6,
15, and 30 d. Reduction of NKG2D-dependent cytotoxicity is particularly evident at day 0 (RMA-S-Rae1 ) and at day 30 (RMA-S-Rae1  and YAC-1).
Note that our RMA-S parental cell line is poorly killed by B6 NK cells although it expresses a low level of MHC class I. Different variants of RMA-S
may be more susceptible to NK cell–mediated lysis.
Figure 3. ADCC, Ly49H-, and Ly49D-dependent cytotoxicity in Vav1,2,3ko and Vav2,3ko NK cells. Cytotoxicity of Vav1,2,3ko (A and B) and
Vav2,3ko (D and E) was tested against EL-4 cells with or without an anti-Thy1.2 mAb as well as Baf-3-m157 and Baf-3. Cytotoxicity of Vav1,2,3ko was
also tested against CHO cells with and without a blocking anti-Ly49D antibody. ADCC was abrogated in both Vav1,2,3ko and Vav2,3ko NK cells;
Ly49H-dependent killing was severely impaired, whereas Ly49D-mediated CHO killing was considerably conserved (C). NK cells were cultured in IL-2
for 10–15 d. In the CHO killing experiment, Ly49D  cells represented 35% of WT and 25% of Vav1,2,3ko NK cell cultures.Cella et al. Brief Definitive Report 821
mediated cytotoxicity, we asked the following: (a) do the
DAP10 and DAP12 pathways trigger ERK1/2 activation;
(b) does the lack of Vav proteins impair DAP10- and/or
DAP12-mediated ERK1/2 activation; and (c) is blockade of
ERK1/2 activation sufficient to inhibit DAP10- and DAP12-
mediated cytotoxicity? To determine whether DAP10 and
DAP12 activate ERK1/2, we analyzed ERK1/2 phosphor-
ylation in lysates from WT, DAP10ko, and DAP12ko NK
cells stimulated via NKG2D at day 7 of IL-2 culture. Both
NKG2D/DAP10 and NKG2D/DAP12 signaling mediated
ERK1/2 phosphorylation (Fig. 4 A). We also observed
marked ERK1/2 phosphorylation in WT NK cells conju-
gated with CHO cells, which was partially reduced in
DAP12ko NK cells. This provides further evidence that
recognition of CHO cells most likely involves receptors
other than Ly49D.
To determine whether Vav deficiency impairs DAP10-
and DAP12-mediated ERK1/2 activation, we cultured WT,
Vav1ko, and Vav1,2,3ko NK cells for 7 d in IL-2 to induce
expression of both NKG2D-L and NKG2D-S and stimu-
lated them with an antibody specific for NKG2D. ERK1/2
phosphorylation was slightly reduced in Vav1ko NK cells and
completely abrogated in Vav1,2,3ko NK cells (Fig. 4 B). In
contrast, no defect of ERK1/2 activation was observed when
Vav1,2,3ko NK cells were conjugated with CHO cells (Fig. 4
B). Thus, there is a consistent correlation between Vav-
dependent changes in ERK1/2 activation and cytotoxicity.
Specifically, in Vav1,2,3ko NK cells, diminished cytotoxicity
is paralleled by disruption of ERK1/2 activation. Conversely,
lysis of CHO cells by Vav1,2,3ko NK cells corresponds with
conserved ERK1/2 activation. The substantial preservation
of ERK1/2 phosphorylation in Vav1ko NK cells most likely
reflects ERK1/2 activation through the Vav2–Vav3 path-
way, which mediates DAP12-mediated cytotoxicity.
To address the impact of impaired ERK1/2 activation on
DAP10- and ITAM-mediated cytotoxicity, we assessed the
effect of a pharmacological inhibitor of MEK on ADCC, ly-
sis of Baf3-m157, and RMAS-Rae1  by WT NK cells,
which selectively express NKG2D-L/DAP10, at day 20 of
IL-2 culture. Remarkably, blockade of ERK1/2 dramatically
reduced NK cell–mediated cytotoxicity in all cases (Fig. 4
C). Identical results were obtained when we tested DAP10ko
and DAP12ko NK cells against RMAS-Rae1  in the pres-
ence of the ERK1/2 inhibitor (unpublished data). Together,
these results suggest that ERK1/2 may be important in link-
ing DAP10–Vav1 and ITAM–Vav2,3 signaling pathways
with exocytosis of lytic granules. However, other down-
stream signaling mediators may be also implicated in DAP10/
Vav1 and ITAM–Vav2,3-mediated cytotoxicity. For exam-
ple, Vav1 may promote the recruitment of PLC 2, which
triggers Ca2  mobilization (20). In addition, Vav proteins
may cooperate with PI-3K, which initiates the PI-3K→
Rac1→PAK1→MEK→ERK cascade (13). Although Vav
proteins mediate signals that regulate cell adhesion and orga-
nization of actin cytoskeleton, conjugation of NK cells with
target cells was not affected by Vav deficiency, excluding a
Figure 4. Effect of Vav deficiency on DAP10- and DAP12-dependent activation of ERK. (A) NKG2D–DAP10 and NKG2D–DAP12 pathways acti-
vate ERK1/2. WT, DAP10ko, and DAP12ko NK cells were incubated at 37 C for the indicated times with anti-NKG2D mAb (left). WT and DAP12ko
NK cells were also conjugated with fixed CHO cells (right). NK cell lysates were analyzed by immunoblotting with antibody against active ERK1/2
(pERK1/2) and anti-ERK1/2. (B) Impact of Vav deficiency on activation of ERK1/2. WT, Vav1ko, and Vav1,2,3ko NK cells (left) were stimulated via
NKG2D as described in A. WT and Vav1,2,3ko NK cells were also conjugated with CHO cells (right). NK cell lysates were analyzed as indicated in A.
(C) MEK inhibitor PD98059 reduces NKG2D-, Fc RIIIA-, and Ly49H-mediated cytotoxicity. IL-2–activated NK cells were preincubated at 37 C for
30 min with PD98059 (50  M) or DMSO and tested for cytolytic activity against RMA-S, RMA-S/Rae1 , EL-4 cells coated with anti-Thy1.2 mAb,
Baf-3, and Baf-3/m157.Vav-dependent and Vav-independent Pathways in NK Cell–mediated Cytotoxicity 822
role of defective adhesion in impairment of NK cell–mediated
lysis (Fig. S4, available at http://www.jem.org/cgi/content/
full/jem.20031847/DC1).
In summary, we investigated the contribution of Vav1,
Vav2, and Vav3 to NK cell cytotoxicity pathways triggered
by individual activating receptors. Our results demonstrate
that Vav1 is essential for DAP10-mediated cytotoxicity,
whereas Vav2 and Vav3 are required for FcR  and DAP12
signaling. Consistent with this conclusion, lack of Vav1
drastically reduced NKG2D-L/DAP10-mediated cytotox-
icity of tumor cells expressing NKG2D ligands, but had no
significant effect on ADCC and Ly49D/DAP12-, Ly49H/
DAP12-, and NKG2D-S/DAP12-mediated cytotoxicity.
In striking contrast, lack of both Vav2 and Vav3 abrogated
ADCC and substantially reduced Ly49H/DAP12- and
NKG2D-S/DAP12-mediated cytotoxicity. Because nei-
ther Vav2ko nor Vav3ko NK cells had obvious cytolitic de-
fects, we suggest that there is functional redundancy be-
tween Vav2 and Vav3.
Early in vitro studies on human NK cells had indicated a
role for Vav1 in natural cytotoxicity against tumor cells and
ADCC (16, 17). Later in vivo studies using Vav1-deficient
mice confirmed that Vav1 is important for natural cytotox-
icity (21, 22). However, they did not conclusively determine
whether Vav1 deficiency globally impairs NK cell–medi-
ated cytotoxicity (21), or selectively affects natural cytotox-
icity and maintains ADCC (22). Our observation that Vav1
is not required for ITAM-mediated cytotoxicity corrobo-
rates and extends the latter model. It has been proposed that
Vav1 may be a crucial target for inhibitory NK cell recep-
tors to prevent NK cell activation and cytotoxicity (25).
Our data suggest that, although Vav1 dephosphorylation
might inhibit the NKG2D–DAP10-dependent pathway, it
would not be sufficient to block all NK cell–activating path-
ways. Previous studies showed that Vav2 is expressed in hu-
man NK cells and enhances their natural and Fc RIIIa-
mediated cytotoxicity (24). Our analysis of Vav2,3ko NK
cells confirms that Vav2 (and Vav3) performs an essential
function in ADCC and extends it to ITAM signaling.
We also analyzed Vav1,2,3ko mice and demonstrated that
lack of all three Vav proteins results in a profound reduc-
tion in NK cell–mediated cytotoxicity. However, we noted
one remarkable exception: Vav1,2,3ko NK cells can effi-
ciently lyse CHO cells. NK cell recognition of CHO cells
is partially mediated by the Ly49D–DAP12 receptor com-
plex, which binds the CHO class I molecule Hm1-C4 (4).
It is possible that, in contrast with Ly49H/DAP12 and
NKG2D-S/DAP12, Ly49D/DAP12 signaling is entirely
Vav independent. However, a more plausible explanation
is that NK cell recognition of CHO cells depends not only
on signals triggered by Ly49D/DAP12, but on multiple
signals transduced by distinct receptors, which integrate
and synergize to reach a critical activating threshold (8).
Some of these CHO cell–specific receptors may be Vav in-
dependent. Therefore, even if weakened by the absence of
all Vav proteins, residual Ly49D/DAP12 signaling may
reach the threshold required for cytotoxicity, if facilitated
by concurrent activating signals transduced by Vav-inde-
pendent receptors. In support of this model, we also ob-
served that the defect of YAC-1 killing by Vav1,2,3ko NK
cells goes beyond that expected based on the impairment of
NKG2D–DAP10 and NKG2D–DAP12 signaling pathways
alone, suggesting that additional YAC-1–specific receptors
may integrate with NKG2D signaling to reach the thresh-
old for the release of lytic granules.
The involvement of Vav1 in NKG2D/DAP10-mediated
signaling in mice shown in this work is in agreement with
the recent demonstration that NKG2D/DAP10 activates
Vav1 in human NK cells (20). It remains to be determined
how DAP10 selectively recruits Vav1, whereas ITAM-
containing adapters mainly signal through Vav2 and Vav3.
Although DAP10 recruits PI-3K, it has been shown that
activation of Vav1 through NKG2D/DAP10 occurs inde-
pendently of PI-3K in human NK cells (20). Thus, DAP10
may recruit Vav1 through adapters such as Grb2 and SLP76
(20). Once recruited, Vav1 may trigger the Rac1→PAK1→
MEK→ERK cascade that elicits cytotoxicity in human NK
cells (13). In addition, Vav1 may facilitate formation of the
SLP76–PLC  complex, PLC-  activation and subsequent
Ca2  mobilization, as previously observed in T cells (15).
DAP12 and FcR  trigger Syk and PI-3K (7), which repre-
sent the most likely mediators of Vav2 and Vav3 activation.
Moreover, Syk allows recruitment of the molecular adaptor
LAT (26), which can recruit PLC 2 independently of
Vav1, possibly explaining why Vav1 is not critical for
DAP12 and FcR  signaling.
Despite the different requirements for Vav proteins, both
DAP10 and DAP12 signaling pathways promoted ERK1/2
activation (Fig. 4 and references 7, 8, 11). ERK1/2 may be
an important link between Vavs and DAP10- and DAP12-
mediated cytotoxicity. Consistent with this, we showed
that deficiency of Vav proteins reduces ERK1/2 activation
and pharmacological inhibition of ERK1/2 activation re-
duces both DAP10- and DAP12-mediated cytotoxicities.
Whether Vav proteins differ in their capacity to recruit ad-
ditional molecules linking DAP10 and ITAM with cyto-
toxicity, such as PLC  (20, 27), remains to be determined.
It is also possible that ITAM→Vav2/Vav3 signaling differs
from DAP10→Vav1 signaling in strength and kinetics. The
former may be more sustained than the latter, allowing not
only for changes in actin cytoskeleton, polarization, and
exocytosis of cytotoxic granules, but also for transcriptional
activation of cytokine genes and cytokine secretion (28).
In agreement with this model, it has been shown that
NKG2D can trigger IFN-  secretion only through DAP12,
not DAP10 (29) and that Vav1 is not required for NK
cell secretion of IFN-  (21). It is not yet known whether
DAP12 and ITAMs require Vav2 and Vav3 to trigger IFN- 
secretion.
Finally, our work illustrates a unique role for the Vav
proteins in NK cells in comparison to T and B cells. Al-
though lack of Vav proteins leads to a profound impair-
ment of T and B cell maturation and function (23), Vav
proteins are dispensable for NK cell development, but areCella et al. Brief Definitive Report 823
required for NK cell effector functions. This result suggests
a fundamental difference in function of the ITAM-contain-
ing signaling adapters, DAP12 and FcR  in NK cells,
CD3  in T cells, and Ig  and Ig  in B cells.
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